JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis Ruchika Sharma19 Dec 2024 12:42 PM ISTDeveloped by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.
IV golimumab for juvenile idiopathic arthritis in shows effective risk-benefit profile: Study Jacinthlyn Sylvia26 Sept 2024 8:00 PM ISTA new study published in the Journal of Rheumatology unveiled that intravenous golimumab for juvenile idiopathic arthritis in a long-term extension...
Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines Ruchika Sharma7 Sept 2022 11:45 AM ISTThis agreement enhances Multicare's oncology, rheumatology, gastroenterology, and ophthalmology, portfolio, which currently consists of three...
Switching to IV golimumab from IV infliximab improves disease activity in RA Medha Baranwal5 April 2022 9:00 AM ISTUSA: Switching to IV-golimumab from IV-infliximab is beneficial in patients with rheumatoid arthritis (RA) as it may improve drug tolerance and...
Cipla Gulf expands partnership with Alvotech for commercialization of 4 biosimilar medicines in Australia, New Zealand Ruchika Sharma2 March 2021 4:26 PM ISTMumbai: Cipla Limited today announced that the company's subsidiary, Cipla Gulf FZ LCC ("Cipla Gulf') is expanding its partnership with Alvotech for...
Golimumab improves insulin production and blood sugar control in T1D: NEJM Medha Baranwal19 Nov 2020 10:00 AM ISTDelhi: Golimumab results in better endogenous insulin production in children and young adults with newly diagnosed overt (stage 3) type 1 diabetes,...
Golimumab may preserve beta-cell function in Type 1 diabetes: Study Hina Zahid21 Jun 2020 11:45 PM ISTBUFFALO, N.Y. - In research led by a University at Buffalo pediatric endocrinologist, a drug called Golimumab showed that it preserved beta-cell...
